SCM
HOWL icon

Sterling Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Sterling Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-414
Closed -$402 – 3317
2025
Q1 		$402 Sell
414
-357
-46% -$467 ﹤0.01% 3000
2024
Q4 		$1.14K Buy
771
+690
+852% +$1.41K ﹤0.01% 2915
2024
Q3 		$172 Buy
+81
New +$184 ﹤0.01% 3134

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Sterling Capital Management's HOWL Position: Q2 2025 in Review

Sterling Capital Management sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 414 shares — an estimated $402 sold.

Sterling Capital Management first reported a position in HOWL in Q3 2024 and held it in 3 quarters. The position peaked at $1.14K in Q4 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Sterling Capital Management reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 414 Werewolf Therapeutics shares in Q2 2025, an estimated $402.
  • Sterling Capital Management first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Werewolf Therapeutics position peaked at $1.14K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.